PL3094345T3 - Immunoterapia oparta na liposomach - Google Patents

Immunoterapia oparta na liposomach

Info

Publication number
PL3094345T3
PL3094345T3 PL15700478T PL15700478T PL3094345T3 PL 3094345 T3 PL3094345 T3 PL 3094345T3 PL 15700478 T PL15700478 T PL 15700478T PL 15700478 T PL15700478 T PL 15700478T PL 3094345 T3 PL3094345 T3 PL 3094345T3
Authority
PL
Poland
Prior art keywords
liposome
based immunotherapy
immunotherapy
Prior art date
Application number
PL15700478T
Other languages
English (en)
Inventor
Daniel Maspoch Comamala
Antonia María Cano Sarabia
Marta VIVES PI
Irma PUJOL AUTONELL
Juan VERDAGUER AUTONELL
Original Assignee
Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol
Fundació Institut Català De Nanociència I Nanotecnologia
Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol, Fundació Institut Català De Nanociència I Nanotecnologia, Institució Catalana De Recerca I Estudis Avançats filed Critical Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol
Publication of PL3094345T3 publication Critical patent/PL3094345T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL15700478T 2014-01-17 2015-01-16 Immunoterapia oparta na liposomach PL3094345T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14151629 2014-01-17
PCT/EP2015/050747 WO2015107140A1 (en) 2014-01-17 2015-01-16 Liposome-based immunotherapy
EP15700478.9A EP3094345B1 (en) 2014-01-17 2015-01-16 Liposome-based immunotherapy

Publications (1)

Publication Number Publication Date
PL3094345T3 true PL3094345T3 (pl) 2018-11-30

Family

ID=49949574

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15700478T PL3094345T3 (pl) 2014-01-17 2015-01-16 Immunoterapia oparta na liposomach

Country Status (12)

Country Link
US (1) US12048765B2 (pl)
EP (1) EP3094345B1 (pl)
JP (2) JP6546195B2 (pl)
CN (1) CN106061502B (pl)
AU (1) AU2015206016B2 (pl)
BR (1) BR112016016356B1 (pl)
CA (1) CA2939435C (pl)
ES (1) ES2672247T3 (pl)
MX (1) MX376783B (pl)
PL (1) PL3094345T3 (pl)
TR (1) TR201807778T4 (pl)
WO (1) WO2015107140A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用
EP3586300A4 (en) * 2017-02-24 2020-12-09 Ebner-Todd, Rene KITCHEN APPLIANCE AND NUTRITION MANAGEMENT
US20220409702A1 (en) * 2019-11-22 2022-12-29 The Research Foundation For The State University Of New York Compositions and methods for use in type 1 diabetes
KR20250115413A (ko) 2022-11-23 2025-07-30 어헤드 테라퓨틱스, 에스.엘. 관용원성 조성물
WO2025083024A1 (en) * 2023-10-16 2025-04-24 Universiteit Utrecht Holding B.V. Improved formulations of autoantigen conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
KR100507660B1 (ko) * 1996-09-13 2005-08-10 리폭센 테크놀로지즈 리미티드 리포좀
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
PT1767216E (pt) 2004-06-11 2012-08-27 Riken Fármaco tendo um ligando de células reguladoras contido num lipossoma
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
WO2007014754A1 (en) * 2005-08-02 2007-02-08 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
EP2217269B1 (en) * 2007-10-12 2017-04-12 Massachusetts Institute of Technology Vaccine nanotechnology
CA2715536C (en) * 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
CN101502649B (zh) * 2008-06-23 2011-11-30 深圳职业技术学院 一种脂质体流感疫苗
US20120164189A1 (en) 2009-07-07 2012-06-28 Balu-Iyer Sathy V Lipidic Compositions for Induction of Immune Tolerance
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EA027259B1 (ru) * 2011-04-29 2017-07-31 Селекта Байосайенсиз, Инк. Наноносители, вырабатывающие иммунную толерантность, для антиген-специфического удаления т-эффекторных клеток
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance
EP3094345B1 (en) * 2014-01-17 2018-03-14 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Liposome-based immunotherapy

Also Published As

Publication number Publication date
EP3094345A1 (en) 2016-11-23
WO2015107140A1 (en) 2015-07-23
CN106061502B (zh) 2021-04-13
MX2016009217A (es) 2017-05-12
TR201807778T4 (tr) 2018-06-21
BR112016016356A2 (pt) 2017-10-03
AU2015206016A1 (en) 2016-08-25
ES2672247T3 (es) 2018-06-13
AU2015206016B2 (en) 2020-07-23
JP2017507171A (ja) 2017-03-16
US20160338953A1 (en) 2016-11-24
EP3094345B1 (en) 2018-03-14
MX376783B (es) 2025-03-07
JP2019196363A (ja) 2019-11-14
JP6546195B2 (ja) 2019-07-17
US12048765B2 (en) 2024-07-30
CN106061502A (zh) 2016-10-26
BR112016016356B1 (pt) 2023-12-26
CA2939435A1 (en) 2015-07-23
CA2939435C (en) 2023-09-19

Similar Documents

Publication Publication Date Title
ZA202005298B (en) Combination tumor immunotherapy
GB201517022D0 (en) No details
GB201410907D0 (en) No details
GB201519531D0 (en) No details
GB201517404D0 (en) No details
SG11201606736YA (en) Compound controls
EP3215182A4 (en) Combination immunotherapy
PT3107573T (pt) Imunoterapia com il-12 visada ao cancro
GB201418217D0 (en) No details
GB201418216D0 (en) No details
GB201412290D0 (en) Novel use
GB201516796D0 (en) No details
GB201517412D0 (en) No details
GB201517574D0 (en) No details
PL3094345T3 (pl) Immunoterapia oparta na liposomach
ZA201803964B (en) Tiled retrofeflector with mutli-stage dicing
GB2541830B (en) Positioning Unit
SG11201700281SA (en) Galectin immunotherapy
GB201517605D0 (en) No details
PL2902575T3 (pl) System okuciowy
GB201417497D0 (en) Novel use
GB201410910D0 (en) No details
GB201402083D0 (en) Retaining means
GB2522661B (en) Context configuration
GB201517502D0 (en) Positioning means